Cephalon Inc - Articles and news items

Cephalon logo

Risk Evaluation and Mitigation Strategy program for FENTORA and ACTIQ

Industry news, News / 13 October 2011 / Cephalon Inc

Healthcare professionals who prescribe & dispense FENTORA® & ACTIQ® can enroll in the REMS program…

Cephalon logo

Cephalon receives FDA approval for Risk Evaluation and Mitigation Strategy for FENTORA and ACTIQ

Industry news, News / 21 July 2011 / Cephalon, Inc.

The FDA approved the Risk Evaluation and Mitigation Strategy for FENTORA® & ACTIQ®…

Cephalon logo

Cephalon shareholders approve acquisition by Teva

Industry news, News / 14 July 2011 / Cephalon Inc.

Cephalon, Inc. announced that its stockholders voted to approve the TEVA proposal to acquire Cephalon…

Cephalon logo

Cephalon granted Temporary Restraining Order in AMRIX® patent litigation

Industry news, News / 20 May 2011 / Cephalon Inc

The United States District Court for the District of Delaware granted a motion filed by plaintiffs Cephalon and Eurand for a TRO enjoining Mylan Pharmaceuticals and Mylan from manufacturing, using and selling its cyclobenzaprine hydrochloride extended-release capsules…


Cephalon presents positive results with NUVIGIL in largest shift work disorder trial ever conducted

Industry news, News / 6 May 2011 / Cephalon Inc

Cephalon, Inc. presented positive results from a phase IV trial…


Teva to acquire Cephalon in $6.8 billion transaction

Industry news, News / 2 May 2011 / Cephalon, Inc.

Teva will acquire all of the outstanding shares of Cephalon for a total enterprise value of approximately $6.8 billion…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...